IL33 and lung carcinoma: Although we cannot currently examine this possibility in human lung cancers because cell lines expressing functional ST2L have not yet been identified, the inhibition of this process by an anti-IL-33 antibody or sST2 may provide a clue for possible treatments to suppress the malignant progression of lung cancers.